Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Squamous Cell Carcinoma of the Oral Cavity or Oropharynx clinical trials

1 of 1 indexed Squamous Cell Carcinoma of the Oral Cavity or Oropharynx trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Squamous Cell Carcinoma of the Oral Cavity or Oropharynx: 1 US clinical trial tracked, 1 recruiting.

Squamous Cell Carcinoma of the Oral Cavity or Oropharynx is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Tobias Todsen, running 1 of these trials.

Enrollment posture brief

Registry condition squamous-cell-carcinoma-of-the-oral-cavity-or-oropharynx

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Squamous Cell Carcinoma (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Squamous Cell Carcinoma of the Oral Cavity or Oropharynx lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Squamous Cell Carcinoma of the Oral Cavity or Oropharynx on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Squamous Cell Carcinoma of the Oral Cavity or Oropharynx is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

Tobias Todsen 1 trials

Named interventions

Most-linked intervention names on Squamous Cell Carcinoma of the Oral Cavity or Oropharynx records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Standard Treatment Other
1 trials
Ultrasound imaging Diagnostic test
1 trials

US sites by state

Facility locations filed on Squamous Cell Carcinoma of the Oral Cavity or Oropharynx trials. A trial with sites in several states counts in each.

Georgia 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Squamous Cell Carcinoma of the Oral Cavity or Oropharynx page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Squamous Cell Carcinoma of the Oral Cavity or Oropharynx trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Tobias Todsen sponsors the most Squamous Cell Carcinoma of the Oral Cavity or Oropharynx trials on record, review their full trial history before evaluating a specific study. See Tobias Todsen's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Squamous Cell Carcinoma of the Oral Cavity or Oropharynx condition card totals 1 registered trials; most-linked intervention Standard Treatment; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.